About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need

Demodex Blepharitis A highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Ocular Rosacea A common inflammatory condition of the eyelid and eyelid margin

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-04 An investigational treatment for ocular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information

Investors Overview

News & Presentations

Events

Financials

Publications Corporate Governance

Stock Information

Other Resources

Patents

XDEMVY^® and/or the method of use of XDEMVY^® may be covered by one or more U.S. and/or foreign patents, including U.S. Patent Nos.: 8,383,659; 10,835,517; 11,197,847; 11,690,826; 11,690,827; and 11,752,137. Other patent applications are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a).